Long-term improvement of slow-channel congenital myasthenic syndrome with fluoxetine

Neuromuscular Disorders

Volumn 16, Issue 5, 2006, Pages 329-333

  Colomer, J ^a   Muller J S ^b   Vernet, A ^a   Nascimento, A ^a   Pons, M ^c   Gonzalez, V ^a   Abicht, A ^b   Lochmuller H ^b  

^a HOSPITAL SANT JOAN DE DÉU   (Spain)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c HOSPITAL SANT JOAN DE DÉU   (Spain)

Author keywords

Congenital myasthenia; Fluoxetine; Slow channel syndrome

Indexed keywords

CHOLINERGIC RECEPTOR; CHOLINESTERASE INHIBITOR; FLUOXETINE; PYRIDOSTIGMINE;

ADOLESCENT; ARTICLE; ASSISTED VENTILATION; CASE REPORT; CONGENITAL MYASTHENIC SYNDROME; DAILY LIFE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; DRUG TREATMENT FAILURE; ELECTROPHYSIOLOGY; ENDURANCE; GENE MUTATION; HOME CARE; HUMAN; LONG TERM CARE; LUNG FUNCTION TEST; MALE; MUSCLE STRENGTH; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RESPIRATORY FUNCTION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

ADOLESCENT; CHOLINESTERASE INHIBITORS; DNA MUTATIONAL ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FLUOXETINE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MUSCLE, SKELETAL; MUTATION; MYASTHENIC SYNDROMES, CONGENITAL; NEUROMUSCULAR JUNCTION; RECEPTORS, CHOLINERGIC; RECEPTORS, NICOTINIC; RECOVERY OF FUNCTION; SEROTONIN UPTAKE INHIBITORS; TIME; TREATMENT OUTCOME;

EID: 33646585179     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2006.02.009     Document Type: Article

References (13)

1. Beeson D., Hantai D., Lochmüller H., and Engel A.G. 126th international workshop: congenital myasthenic syndromes, 24-26 September 2004, Naarden, The Netherlands. Neuromuscul Disord 15 (2005) 498-512
2. Engel A.G., Lambert E.H., Mulder D.M., et al. A newly recognized congenital myasthenic syndrome attributed to a prolonged open time of the acetylcholine-induced ion channel. Ann Neurol 11 (1982) 553-569
3. Engel A.G., Ohno K., Milone M., et al. New mutations in acetylcholine receptor subunit genes reveal heterogeneity in the slow-channel congenital myasthenic syndrome. Hum Mol Genet 5 (1996) 1217-1244
4. Harper C.M., and Engel A.G. Quinidine sulfate therapy for the slow-channel congenital myasthenic syndrome. Ann Neurol 43 (1998) 480-484
5. Harper C.M., Fukodome T., and Engel A.G. Treatment of slow-channel congenital myasthenic syndrome with fluoxetine. Neurology 60 (2003) 1710-1713
6. Abicht A., Stucka R., Karcagi V., et al. A common mutation (epsilon1267delG) in congenital myasthenic patients of Gypsy ethnic origin. Neurology 53 (1999) 1564-1573
7. Gomez C.M., and Gammack J.T. A leucine-to-phenylalanine substitution in the acetylcholine receptor ion channel in a family with the slow-channel syndrome. Neurology 45 (1995) 982-987
8. Lundmark J., Reis M., and Bengtsson S. Concentration of fluoxetine in the clinical treatment setting. Ther Drug Monit 23 (2001) 139-147
9. Croxen R., Newland C., Beeson D., et al. Mutations in different functional domains of the human muscle acetylcholine receptor alpha subunit in patients with the slow-channel congenital myasthenic syndrome. Hum Mol Genet 6 (1997) 767-774
10. Croxen R, Hatton C, Shelley C, et al. Recessive inheritance and variable penetrance of slow-channel congenital myasthenic syndromes. Neurology; 59:162-8.
11. Hutchinson D.O., Walls T.J., Nakano S., et al. Congenital endplate acetylcholinesterase deficiency. Brain 116 (1993) 633-653
12. Shapira Y.A., Sadeh M.E., Bergtraum M.P., et al. Three novel COLQ mutations and variation of phenotypic expressivity due to G240X. Neurology 58 (2002) 603-609
13. Stoll Al., Pope H.G., and McElroy S.M. High-dose fluoxetine: safety and efficacy in 27 cases. J Clin Pharmacol 11 (1991) 225-226